Claudio Vernieri

4.5k total citations
91 papers, 1.8k citations indexed

About

Claudio Vernieri is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Claudio Vernieri has authored 91 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 32 papers in Cancer Research and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Claudio Vernieri's work include Advanced Breast Cancer Therapies (18 papers), Neuroendocrine Tumor Research Advances (14 papers) and Breast Cancer Treatment Studies (14 papers). Claudio Vernieri is often cited by papers focused on Advanced Breast Cancer Therapies (18 papers), Neuroendocrine Tumor Research Advances (14 papers) and Breast Cancer Treatment Studies (14 papers). Claudio Vernieri collaborates with scholars based in Italy, United States and France. Claudio Vernieri's co-authors include Filippo de Braud, Valter D. Longo, Riccardo Lobefaro, Marco Foiani, Francesca Ligorio, Andrea Ciliberto, Giuseppe Capri, Giulia Bianchi, Stefano Santaguida and Fabrizio Villa and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Claudio Vernieri

85 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claudio Vernieri Italy	21	845	781	418	322	203	91	1.8k
Daniele Avanzato Italy	15	465 0.6×	996 1.3×	338 0.8×	236 0.7×	120 0.6×	18	1.8k
Stephan Singer Germany	28	458 0.5×	1.2k 1.5×	468 1.1×	201 0.6×	279 1.4×	76	2.1k
Veronica Vella Italy	31	677 0.8×	1.4k 1.8×	590 1.4×	131 0.4×	81 0.4×	68	2.6k
Bruna Corominas-Faja Spain	28	770 0.9×	1.5k 2.0×	748 1.8×	228 0.7×	107 0.5×	36	2.2k
Linda Beltrán United States	24	577 0.7×	1.1k 1.4×	385 0.9×	192 0.6×	151 0.7×	42	1.8k
Takako Asano Japan	27	378 0.4×	1.3k 1.7×	469 1.1×	412 1.3×	227 1.1×	84	2.1k
Mi Ran Yun South Korea	22	558 0.7×	622 0.8×	268 0.6×	483 1.5×	54 0.3×	49	1.4k
Haijuan Wang China	23	526 0.6×	896 1.1×	322 0.8×	159 0.5×	89 0.4×	66	1.6k
Hung‐Ming Lam United States	24	770 0.9×	1.1k 1.4×	494 1.2×	766 2.4×	124 0.6×	57	2.5k
Alison F. Munro United Kingdom	26	855 1.0×	850 1.1×	557 1.3×	285 0.9×	79 0.4×	54	2.2k

Countries citing papers authored by Claudio Vernieri

Since Specialization

Citations

This map shows the geographic impact of Claudio Vernieri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudio Vernieri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudio Vernieri more than expected).

Fields of papers citing papers by Claudio Vernieri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudio Vernieri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudio Vernieri. The network helps show where Claudio Vernieri may publish in the future.

Co-authorship network of co-authors of Claudio Vernieri

This figure shows the co-authorship network connecting the top 25 collaborators of Claudio Vernieri. A scholar is included among the top collaborators of Claudio Vernieri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudio Vernieri. Claudio Vernieri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Xingrong, Davide Massa, Nikos Tsiknakis, et al.. (2025). Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study. The Lancet Regional Health - Europe. 58. 101432–101432.

Martelli, Gabriele, Francesco Barretta, Chiara Listorti, et al.. (2025). Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional Study. Annals of Surgical Oncology. 33(3). 2255–2266.

Miglietta, Federica, Claudio Vernieri, Matilde Cacciatore, et al.. (2024). Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab.. Journal of Clinical Oncology. 42(16_suppl). 1100–1100.

Raucci, Franca, Claudio Vernieri, Maira Di Tano, et al.. (2024). Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia. Cancer Research. 84(7). 1133–1148. 5 indexed citations

Botticelli, Andrea, Alessandra Fabi, Alessandro Rossi, et al.. (2024). Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study.. Journal of Clinical Oncology. 42(16_suppl). 1032–1032. 1 indexed citations

Vernieri, Claudio, Francesca Ligorio, Claudia De Angelis, et al.. (2023). 352TiP Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial. Annals of Oncology. 34. S322–S323. 2 indexed citations

Ferrando, Lorenzo, Andrea Vingiani, Anna Garuti, et al.. (2023). ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PLoS Genetics. 19(1). e1010563–e1010563. 7 indexed citations

Ligorio, Francesca, Lorenzo Castagnoli, Andrea Vingiani, et al.. (2021). Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. Cancer Letters. 511. 77–87. 31 indexed citations

Pusceddu, Sara, Claudio Vernieri, Natalie Prinzi, et al.. (2020). The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. Therapeutic Advances in Gastroenterology. 13. 3974116135–3974116135. 9 indexed citations

10.

Mirabile, Aurora, Licia Rivoltini, Elena Daveri, et al.. (2020). Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. Cancers. 12(5). 1153–1153. 4 indexed citations

11.

Zattarin, Emma, Chiara Fabbroni, Francesca Ligorio, et al.. (2020). 300P Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study. Annals of Oncology. 31. S362–S363. 2 indexed citations

12.

Ligorio, Francesca, Lorenzo Castagnoli, Emma Zattarin, et al.. (2020). 175P Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)–positive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy. Annals of Oncology. 31. S312–S312. 1 indexed citations

13.

Vernieri, Claudio, Alessandra Raimondi, Francesca Ligorio, et al.. (2020). 146P Safety and metabolic effects of fasting-mimicking diet in breast cancer patients. Annals of Oncology. 31. S68–S68. 1 indexed citations

14.

Chiroli, Elena, Fridolin Groß, Claudio Vernieri, et al.. (2019). Cellular response upon proliferation in the presence of an active mitotic checkpoint. Life Science Alliance. 2(3). e201900380–e201900380. 2 indexed citations

15.

Chiroli, Elena, Fridolin Groß, Claudio Vernieri, et al.. (2017). Cells Escape an Operational Mitotic Checkpoint through a Stochastic Process. Current Biology. 28(1). 28–37.e7. 14 indexed citations

16.

Cavalieri, Stefano, Alessandra Raimondi, Daniele Morelli, et al.. (2016). Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging. Annals of Oncology. 27. iv13–iv13. 1 indexed citations

17.

Pusceddu, Sara, Giuseppe Lo Russo, Silvia Ortolani, et al.. (2016). Update on medical treatment of small intestinal neuroendocrine tumors. Expert Review of Anticancer Therapy. 16(9). 969–976. 4 indexed citations

18.

Buzzoni, Roberto, Natalie Prinzi, Laura Concas, et al.. (2016). Safety of Lanreotide 120 mg ATG in combination with metformin in patients with progressive advanced well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prospective study: the MetNET-2 trial. Annals of Oncology. 27. iv25–iv25. 1 indexed citations

19.

Vernieri, Claudio, Sara Pusceddu, Carlo Capella, et al.. (2016). Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities A Case Report with a 6-Year Follow-Up. Case Reports in Oncology. 9(2). 432–439. 4 indexed citations

20.

Crespo, Carolina Lage, Claudio Vernieri, Philipp Keller, et al.. (2014). The PAR complex controls the spatiotemporal dynamics of F-actin and the MTOC in directionally migrating leukocytes. Journal of Cell Science. 127(Pt 20). 4381–95. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact